Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size and Outlook 2030

Report Description

Forecast Period	2026-2030
Market Size (2024)	USD 8.19 Billion
CAGR (2025-2030)	7.61%
Fastest Growing Segment	Chemotherapy
Largest Market	North America
Market Size (2030)	USD 12.72 Billion

Market Overview

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market , valued at USD 8.19 Billion in 2024, is projected to experience a CAGR of 7.61% to reach USD 12.72 Billion by 2030. Non-Hodgkin Lymphoma (NHL) therapeutics comprise a range of medical treatments designed to manage and combat this diverse group of blood cancers originating within the lymphatic system. These therapies, encompassing chemotherapy, targeted therapy, immunotherapy, radiation, and stem cell transplantation, aim to eliminate malignant cells and improve patient outcomes. The market’s expansion is primarily driven by the increasing global incidence of NHL; for instance, according to the American Cancer Society, an estimated 80,550 new cases of Non-Hodgkin Lymphoma were diagnosed in the U. S. in January 2023.

Further market support stems from advancements in novel targeted and immunotherapies, coupled with rising government healthcare expenditure. According to the Leukemia & Lymphoma Society, approximately 80,620 people in the U. S. were expected to be diagnosed with non-Hodgkin lymphoma in 2024. However, a significant challenge impeding market expansion is the high cost associated with advanced therapeutic modalities, such as certain immunotherapies, which can limit patient access and pose reimbursement complexities.

Key Market Drivers

Advancements in immunotherapy and CAR T-cell therapies are a primary driver for the Non-Hodgkin Lymphoma therapeutics market, introducing highly effective and specialized treatments. These modalities utilize the patient's immune system or engineered immune cells to precisely target and eliminate cancer cells, offering transformative outcomes for aggressive or refractory NHL. Their increasing adoption, including expansion into earlier lines of treatment, significantly boosts market value. According to Gilead Sciences' full year 2024 financial results, released in February 2025, Cell Therapy product sales, encompassing NHL therapies like Yescarta, increased by 6% to reach $2.0 billion in the full year 2024 compared to 2023, reflecting substantial commercial success and clinical integration.

Innovations in targeted therapies also critically drive market expansion by focusing on specific molecular pathways essential for cancer cell growth, yielding more precise and less toxic treatment options. The continuous development and market introduction of novel targeted agents, such as antibody-drug conjugates, broaden the patient landscape and address unmet needs across various NHL subtypes. For example, according to Roche's 2024 financial results, released in January 2025, Polivy (polatuzumab vedotin), an antibody-drug conjugate for diffuse large B-cell lymphoma, achieved full-year sales of 1.12 billion Swiss francs, demonstrating notable market penetration. This therapeutic innovation is further propelled by substantial research funding; Blood Cancer United, formerly The Leukemia & Lymphoma Society, reported $332.2 million in multi-year research commitments across blood cancers in its 2024 annual report, directly fueling market growth and pipeline development.

Download Free Sample Report

Key Market Challenges

The high cost associated with advanced therapeutic modalities presents a significant impediment to the growth of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market. Modern treatments, particularly immunotherapies, often feature substantial price tags. This directly limits patient access to potentially life-saving or life-extending therapies, especially in healthcare systems with stringent budgetary controls or for individuals with inadequate insurance coverage. Even for patients with coverage, significant out-of-pocket expenses can lead to treatment delays or abandonment, compromising optimal patient outcomes.

Reimbursement complexities further exacerbate this challenge, as payers and healthcare providers navigate intricate approval processes for expensive advanced treatments. According to a review published in *The Oncologist* in 2025 concerning anticancer therapies, launch prices for 95% of new anticancer therapies exceeded $100,000 per year in 2023. Such high costs strain healthcare budgets, leading to increased scrutiny and potential denials or restrictive criteria for coverage, particularly for novel NHL therapeutics. This financial burden on patients and healthcare systems slows the adoption rate of new therapies, thereby directly hampering overall market expansion despite clinical advancements.

Key Market Trends

A significant trend driving the Global Non-Hodgkin Lymphoma therapeutics market is the robust pipeline development and continuous launch of novel drugs. This trend signifies a broader expansion of therapeutic options beyond established categories, addressing diverse patient needs and resistance mechanisms. According to OncLive, almost 20 FDA approvals occurred in the hematology sphere in 2024, demonstrating consistent innovation across blood cancers. This influx of new treatments provides clinicians with more tools to manage the complex and varied subtypes of NHL, including those that are aggressive or refractory. For instance, data presented at the 2025 American Society of Clinical Oncology meeting highlighted updates from the STARGLO study on glofitamab for relapsed or refractory diffuse large B-cell lymphoma, demonstrating that the overall survival benefit on the glofitamab plus gemox arm maintained more than 50% of patients remaining alive in a two-year data set. This indicates the sustained impact of pipeline advancements on patient outcomes.

Another prominent trend influencing the market is the integration of artificial intelligence in therapeutic planning. AI technologies are increasingly leveraged to optimize treatment strategies and accelerate drug discovery, offering more personalized and efficient approaches. According to a 2024 ICON survey, nearly half, specifically 49%, of oncology researchers identified AI and machine learning as the area most likely to accelerate oncology drug development. This growing recognition of AI's potential translates into strategic collaborations aimed at transforming pharmaceutical research. In November 2023, Roche's Genentech unit partnered with computing giant Nvidia in a multiyear deal to significantly enhance its AI research capabilities, aiming to speed up the process of designing and developing new drugs. Such integrations are crucial for streamlining complex data analysis and predicting therapeutic responses, thereby improving decision-making in clinical settings for NHL.

Segmental Insights

In the Global Non-Hodgkin Lymphoma Therapeutics Market, the chemotherapy segment is experiencing the most rapid expansion. This growth is primarily attributable to chemotherapy's broad applicability across numerous NHL subtypes, making it a foundational treatment modality despite the introduction of newer therapies. Its well-established protocols and high familiarity among healthcare professionals contribute significantly to its sustained demand. Furthermore, advancements such as dose-dense regimens and novel maintenance schedules have enhanced tolerability and broadened its utility, including for older patient populations. Chemotherapy also remains a cost-effective treatment option, particularly in regions with limited resources, further driving its adoption.

Regional Insights

North America leads the Global Non-Hodgkin Lymphoma Therapeutics Market, driven by its advanced healthcare infrastructure and robust research and development ecosystem. The region benefits from significant investments in cancer therapies and a favorable regulatory environment, facilitating expedited drug approvals. For instance, the processes managed by the U. S. Food and Drug Administration support rapid access to novel treatments. Additionally, the strong presence of major pharmaceutical companies, leading academic research institutions, and comprehensive reimbursement policies collectively ensure the early adoption and widespread availability of innovative therapies, solidifying North America's dominant market position.

Recent Developments

In June 2025, Galapagos NV unveiled new data from its ongoing ATALANTA-1 Phase 1/2 study of investigational CD19 CAR T-cell therapy, GLPG5101, at the International Conference on Malignant Lymphoma. This breakthrough research highlighted high complete response and minimal residual disease negativity rates in heavily pretreated patients with relapsed or refractory indolent non-Hodgkin lymphoma. Notably, the study emphasized a rapid vein-to-vein time, with a majority of patients receiving a fresh, non-cryopreserved product. These results indicate promising efficacy and a favorable safety profile for this innovative CAR T-cell therapy, contributing to advancements in the Global Non-Hodgkin Lymphoma Therapeutics Market.

In December 2024, Regeneron Pharmaceuticals presented new and updated data for odronextamab, an investigational CD20xCD3 bispecific antibody, at the American Society of Hematology Annual Meeting. The presentations showcased breakthrough research across several B-cell non-Hodgkin lymphoma (NHL) subtypes, including initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial. This trial demonstrated complete responses in all evaluable patients with previously untreated follicular lymphoma. These findings underscore the potential of odronextamab to become a core therapy, addressing unmet needs in earlier lines of treatment within the Global Non-Hodgkin Lymphoma Therapeutics Market.

In June 2024, AbbVie and Genmab announced that the U.S. Food and Drug Administration granted accelerated approval for epcoritamab-bysp (EPKINLY®) as a monotherapy for adult patients with relapsed or refractory follicular lymphoma after two or more prior systemic therapies. This subcutaneous T-cell engaging bispecific antibody, developed through their oncology partnership, represents a new product launch in the Global Non-Hodgkin Lymphoma Therapeutics Market. The decision was supported by compelling data from the Phase 1/2 EPCORE® NHL-1 clinical trial, which highlighted the drug's efficacy and safety profile for this difficult-to-treat Non-Hodgkin Lymphoma subtype.

In May 2024, Bristol Myers Squibb received accelerated approval from the U.S. Food and Drug Administration for lisocabtagene maraleucel (Breyanzi) to treat adult patients with relapsed or refractory follicular lymphoma who had undergone at least two prior lines of systemic therapy. This significant development expanded the available chimeric antigen receptor (CAR) T-cell therapy options within the Global Non-Hodgkin Lymphoma Therapeutics Market. The approval was based on data from the Phase 2 TRANSCEND FL trial, which demonstrated promising response rates and duration of response in this patient population, addressing an unmet need for effective treatments in a common subtype of Non-Hodgkin Lymphoma.

Key Market Players

AstraZeneca PLC
Baxter International Inc.
Bayer AG
Novartis AG
Eli Lilly and Company.
Spectrum Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb Company
GlaxoSmithKline PLC
Janssen Pharmaceuticals, Inc.

By Type of Therapy	By Cell Type	By Drug Type	By Distribution Channel	By Region
Immunotherapy Targeted Therapy Chemotherapy Stem Cell Transplant Others	B-cell Lymphomas T-cell Lymphomas	Revlimid Rituxan Keytruda Imbruvica Opdivo Others	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Type of Therapy:

o Immunotherapy

o Targeted Therapy

o Chemotherapy

o Stem Cell Transplant

o Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Cell Type:

o B-cell Lymphomas

o T-cell Lymphomas

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Drug Type:

o Revlimid

o Rituxan

o Keytruda

o Imbruvica

o Opdivo

o Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Distribution Channel:

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

o Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market .

Available Customizations:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)

5.2.2. By Cell Type (B-cell Lymphomas, T-cell Lymphomas)

5.2.3. By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)

5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)

5.2.5. By Region

5.2.6. By Company (2024)

5.3. Market Map

6. North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type of Therapy

6.2.2. By Cell Type

6.2.3. By Drug Type

6.2.4. By Distribution Channel

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type of Therapy

6.3.1.2.2. By Cell Type

6.3.1.2.3. By Drug Type

6.3.1.2.4. By Distribution Channel

6.3.2. Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type of Therapy

6.3.2.2.2. By Cell Type

6.3.2.2.3. By Drug Type

6.3.2.2.4. By Distribution Channel

6.3.3. Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Type of Therapy

6.3.3.2.2. By Cell Type

6.3.3.2.3. By Drug Type

6.3.3.2.4. By Distribution Channel

7. Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type of Therapy

7.2.2. By Cell Type

7.2.3. By Drug Type

7.2.4. By Distribution Channel

7.2.5. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type of Therapy

7.3.1.2.2. By Cell Type

7.3.1.2.3. By Drug Type

7.3.1.2.4. By Distribution Channel

7.3.2. France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type of Therapy

7.3.2.2.2. By Cell Type

7.3.2.2.3. By Drug Type

7.3.2.2.4. By Distribution Channel

7.3.3. United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type of Therapy

7.3.3.2.2. By Cell Type

7.3.3.2.3. By Drug Type

7.3.3.2.4. By Distribution Channel

7.3.4. Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Type of Therapy

7.3.4.2.2. By Cell Type

7.3.4.2.3. By Drug Type

7.3.4.2.4. By Distribution Channel

7.3.5. Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Type of Therapy

7.3.5.2.2. By Cell Type

7.3.5.2.3. By Drug Type

7.3.5.2.4. By Distribution Channel

8. Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type of Therapy

8.2.2. By Cell Type

8.2.3. By Drug Type

8.2.4. By Distribution Channel

8.2.5. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type of Therapy

8.3.1.2.2. By Cell Type

8.3.1.2.3. By Drug Type

8.3.1.2.4. By Distribution Channel

8.3.2. India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type of Therapy

8.3.2.2.2. By Cell Type

8.3.2.2.3. By Drug Type

8.3.2.2.4. By Distribution Channel

8.3.3. Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type of Therapy

8.3.3.2.2. By Cell Type

8.3.3.2.3. By Drug Type

8.3.3.2.4. By Distribution Channel

8.3.4. South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Type of Therapy

8.3.4.2.2. By Cell Type

8.3.4.2.3. By Drug Type

8.3.4.2.4. By Distribution Channel

8.3.5. Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Type of Therapy

8.3.5.2.2. By Cell Type

8.3.5.2.3. By Drug Type

8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type of Therapy

9.2.2. By Cell Type

9.2.3. By Drug Type

9.2.4. By Distribution Channel

9.2.5. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type of Therapy

9.3.1.2.2. By Cell Type

9.3.1.2.3. By Drug Type

9.3.1.2.4. By Distribution Channel

9.3.2. UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type of Therapy

9.3.2.2.2. By Cell Type

9.3.2.2.3. By Drug Type

9.3.2.2.4. By Distribution Channel

9.3.3. South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type of Therapy

9.3.3.2.2. By Cell Type

9.3.3.2.3. By Drug Type

9.3.3.2.4. By Distribution Channel

10. South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Type of Therapy

10.2.2. By Cell Type

10.2.3. By Drug Type

10.2.4. By Distribution Channel

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type of Therapy

10.3.1.2.2. By Cell Type

10.3.1.2.3. By Drug Type

10.3.1.2.4. By Distribution Channel

10.3.2. Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Type of Therapy

10.3.2.2.2. By Cell Type

10.3.2.2.3. By Drug Type

10.3.2.2.4. By Distribution Channel

10.3.3. Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Type of Therapy

10.3.3.2.2. By Cell Type

10.3.3.2.3. By Drug Type

10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market : SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. AstraZeneca PLC

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Baxter International Inc.

15.3. Bayer AG

15.4. Novartis AG

15.5. Eli Lilly and Company.

15.6. Spectrum Pharmaceuticals, Inc.

15.7. Teva Pharmaceutical Industries Ltd.

15.8. Bristol Myers Squibb Company

15.9. GlaxoSmithKline PLC

15.10. Janssen Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market in 2024?

Which is the dominating region in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market ?

Which is the fastest growing segment in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market ?

What is the expected growth rate of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market ?